/
Recursion is a clinical-stage TechBio company with a mission to decode biology to radically improve lives. We have advanced a portfolio of differentiated internal programs and strategic partnerships powered by our integrated drug discovery and development platform, the Recursion Operating System (OS).
$3.01
$0.10 (-3.22%)
Price from 14 days ago
The business is unprofitable at the operating level (-867.87% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 26.9%, still solid. Margins contracted 53.8pp, which offsets some of the top-line progress.
Negative free cash flow of -$378M. The business is consuming cash, not generating it. Operating margin contracted 53.8pp YoY, cost discipline may be slipping.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$66M
▲ +26.9% YoY
Net Income (TTM)
-$560M
▼ -39.1% YoY
Op. Margin
-881.32%
▼ -53.8pp YoY
ROIC
-43.57%
▲ +2.2pp YoY
Cash Flow & Balance Sheet
FCF (FY)
-$378M
▼ -1.5% YoY
Op. Cash Flow (FY)
-$372M
▼ -3.5% YoY
Net Debt
-$645M
Net Cash Position
Cash & Equiv.
$654M
5Y CAGR: +79.9%
Continue Research